| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 123,575 | 98,804 | ||
| Marketable securities | 196,049 | 177,986 | ||
| Prepaid expenses and other current assets | 8,577 | 5,424 | ||
| Total current assets | 328,201 | 282,214 | ||
| Restricted cash | 1,585 | 1,584 | ||
| Marketable securities, non-current | 0 | 20,059 | ||
| Other investments | 19,000 | 19,000 | ||
| Property and equipment, net | 36,722 | 39,115 | ||
| Operating lease right-of-use assets | 19,912 | 20,951 | ||
| Other non-current assets | 2,545 | 2,530 | ||
| Total assets | 407,965 | 385,453 | ||
| Accounts payable | 2,568 | 3,379 | ||
| Accrued liabilities and other current liabilities | 29,310 | 27,999 | ||
| Contingent consideration payable | 0 | 5,525 | ||
| Total current liabilities | 31,878 | 36,903 | ||
| Operating lease liabilities, non-current | 44,285 | 46,597 | ||
| Other non-current liabilities | 2,681 | 3,030 | ||
| Total liabilities | 78,844 | 86,530 | ||
| Common stock, value, issued | 2 | 1 | ||
| Additional paid-in capital | 1,807,749 | 1,738,850 | ||
| Accumulated other comprehensive income | 201 | 57 | ||
| Accumulated deficit | -1,478,831 | -1,439,985 | ||
| Total stockholders equity | 329,121 | 298,923 | ||
| Total liabilities and stockholders equity | 407,965 | 385,453 | ||
Lyell Immunopharma, Inc. (LYEL)
Lyell Immunopharma, Inc. (LYEL)